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FLIMa b s t r a c t
Actinic Keratosis’ (AKs) are small skin lesions that are related to a prolonged sun-damage, which can
develop into invasive squamous cell carcinoma (SCC) when left untreated. Effective, specific and well tol-
erable therapies to cure AKs are still of great interest. Diclofenac (DCF) is the current gold standard for the
local treatment of AKs in terms of costs, effectiveness, side effects and tolerability. In this work, an elec-
trospun polylactic acid (PLA) scaffold loaded with a synthetic DCF prodrug was developed and character-
ized. Specifically, the prodrug was successfully synthetized by binding DCF to a glycine residue via solid
phase peptide synthesis (SPPS) and then incorporated in an electrospun PLA scaffold. The drug encapsu-
lation was verified using multiphoton microscopy (MPM) and its scaffold release was spectrophotomet-
rically monitored and confirmed with MPM. The scaffold was further characterized with scanning
electron microscopy (SEM), tensile testing and contact angle measurements. Its biocompatibility was ver-
ified by performing a cell proliferation assay and compared to PLA scaffolds containing the same amount
of DCF sodium salt (DCFONa). Finally, the effect of the electrospun scaffolds on human dermal fibroblasts
(HDFs) morphology and metabolism was investigated by combining MPM with fluorescence lifetime
imaging microscopy (FLIM). The obtained results suggest that the obtained scaffold could be suitable
for the controlled and targeted delivery of the synthesized prodrug for the treatment of AKs.
Statement of Significance
Electrospun scaffolds are of growing interest as materials for a controlled drug delivery. In this work, an
electrospun polylactic acid scaffold containing a synthetically obtained Diclofenac prodrug is proposed as
a novel substrate for the topical treatment of actinic keratosis. A controlled drug delivery targeted to the
area of interest could enhance the efficacy of the therapy and favor the healing process. The prodrug was
synthesized via solid phase, employing a clean and versatile approach to obtain Diclofenac derivatives.
Here, we used multiphoton microscopy to image drug encapsulation within the fibrous scaffold and flu-
orescence lifetime imaging microscopy to investigate Diclofenac effects and potential mechanisms of
action.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The medical term ‘‘actinic keratosis (AK)” identifies small skin
lesions, which appear as round, rough spots between 5 mm and
1 cm in diameter. AKs are characterized as pre-cancerous or as
early-stage tumors [1,2]. This pathology is also known as ‘‘solar
keratosis” or ‘‘senile keratosis” because it is more common to peo-btained
2 G. Piccirillo et al. / Acta Biomaterialia xxx (2016) xxx–xxxple over 50 with fair skin and is related to a prolonged sun-damage
[1]. This process, also known as photoaging, leads to an accumula-
tion of oncogenic changes [2]. Changes related to photodamage are
most evident in the extracellular matrix (ECM) [3]. The accumula-
tion of these changes leads to a pathological ECMmainly due to the
degradation and fragmentation of its components such as elastic
fibers [4]. As a result, the normal repair and regenerative capacity
of the ECM is inhibited [4,5]. Skin ageing processes also have a sig-
nificant impact on cellular mechanisms such as DNA repair, gene
expression and immune response modulation [5]. AK is considered
a key event in the progression from photoaged skin to the invasive
squamous cell carcinoma (SCC) [2,6]. SCC affects the keratinocytes
of the epidermis layer and is the second most diffused skin cancer
after the basal cell carcinoma (bcc) [1,7]. However, there are many
more AKs than SCCs and it is difficult to predict exactly which
lesions will progress to invasive cancer [1,2]. About 15% of the
men and 6% of the women in Europe are affected by AKs. The per-
centages rise respectively to 34% and 18% in the European popula-
tion over 70 years of age [7]. Since the average life expectancy is
increasing, it is predicted that even more people will be affected
by AKs in the next years [1,2,7]. Although a number of treatments
are already available [8–10], the development of effective, more
targeted and well-tolerable therapies for the treatment of AKs is
still of great interest. The first therapy approved by the Food and
Drug Administration (FDA) for the topical treatment of AKs was
5-Fluorouracil in 1962 [8] followed by Imiquimod in 1997 [8],
Diclofenac (DCF) in 2002 [9,10] and Ingenol Mebutate in 2012
[9]. Among them, DCF is currently the therapy of choice in terms
of costs, effectiveness, side effects and tolerability [10]. DCF
belongs to the class of non-steroidal anti-inflammatory drugs
(NSAIDs) and is one of the most commonly used in the world
[11]. It is still not clear how DCF affects AKs, but its activity seems
to be related to anti-inflammatory and anti-angiogenic effects [12].
Induced apoptosis has been also proposed as a possible DCF mech-
anism of action in the treatment of AKs [13]. The absorption of a
drug through the outermost layer of the skin, the stratum corneum
(SC), is limited [14]. Thus a specific formulation of DCF commer-
cially known as Solaraze is needed for the treatment of AKs. This
formulation is supplied with hyaluronic acid that enables DCF
accumulation in the epidermis [15]. Considering these aspects, a
chemical modification of DCF that enhances its permeation
through the SC is of interest since it could improve its efficacy
against AKs.
Over the last two decades, electrospinning has gained growing
interest as a potential polymer processing technique for applica-
tions in tissue engineering [16,17] and drug delivery [18]. Electro-
spinning is a process that uses a high voltage source to apply a
charge of a certain polarity into a polymer solution or melt, which
is then accelerated toward a collector of opposite polarity. Electro-
spinning is an easy way to fabricate fiber-containing scaffolds with
a fiber diameter in the nano- to micrometer size scale that mimic
the structure and morphology of the ECM components in the skin
[16,17,19]. Biodegradable and natural materials can be electro-
spun, and a wide range of molecules like drugs and proteins can
be incorporated in the scaffolds [18]. Polylactic acid (PLA) is a
biodegradable, biocompatible polymer with beneficial mechanical
properties. Moreover, it is stable over a long time and its degrada-
tion proceeds through the hydrolysis of the ester linkage in the
polymer’s backbone resulting in a non-toxic degradation product
called lactic acid [20].
In this study, we aimed to encapsulate a chemical modified and
synthetically produced DCF prodrug in an electrospun PLA scaffold
in order to obtain a suitable drug delivery system to locally treat
AKs. A controlled and targeted drug delivery to the region of inter-
est could reduce the undesired side-effects and enhance the effi-
cacy of the therapy.Please cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
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2.1. Synthesis of DCF-Glycine (DCF-Gly) prodrug
All coupling reagents were purchased from Novabiochem (EMD
Millipore by Merck KGaA, Darmstadt, Germany). 2-Chlorotrityl
chloride resin preloaded with glycine (H-Gly-2ClTrt Resin), the sol-
vents and DCF sodium salt (DCFONa) were purchased by Sigma
Aldrich (Steinheim, Germany). DCF free acid was obtained by the
dissolution of the sodium salt in water followed by acidification
and extraction [21]. For the synthesis, H-Gly-2ClTrt resin
(227 mg, 0.250 mmol, substitution 1.1 mmol/g, mesh 75–150)
was suspended in a solvent mixture (Dimethylformamide(DMF):
Dichloromethane (DCM) = 1:1, Vf = 10 mL) using a glass frittered
disk sealed in glass column equipped with a faucet. The suspension
was stirred (250 rpm) for 2 h using an orbital shaker. The solvent
was then removed by filtration and 8 mL of a DCM:DMF = 1:1 solu-
tion containing 148 mg (0.5 mmol) of DCF, 520 mg (1 mmol) of Ben
zotriazol-1-yloxy-tripyrrolidino- phosphoniumhexafluoropho
sphate (PyBOP) and 150 mg (1 mmol) of 1-Hydroxybenzotriazole
hydrate (HOBT) were added to the resin. After shaking the mixture
manually for a few minutes, 175 lL (1 mmol) of N,N-
Diisopropylethylamine (DIPEA) was added and the mixture was
shaken (280 rpm) using an orbital shaker for 20 h. Thereafter, the
solvent was removed by filtration, the resin was washed
(2x10 mL DMF, 3x10 mL Methanol (MeOH), 2x10 mL DMF,
3x10 mL DCM), and the functionalized amino acid was cleaved
by adding 10 mL of a mixture of acetic acid (AcOH):2,2,2-
Trifluoroethanol (TFE):DCM = 1:1:8. The solution was shaken
(250 rpm) employing an orbital shaker for 30 min. The cleavage
mixture was then filtered, and the resin was washed with DCM
(3x5 mL). The filtrates were combined and evaporated under
reduced pressure to 5% of the initial volume, and 10 mL of double
distilled water was then added to precipitate the desired product.
The final product was lyophilized twice to remove any solvent
residual, and recovered as a white fluffy powder in a final yield
of 98% (86.5 mg, 0.245 mmol).2.2. Nuclear magnetic resonance (NMR) analysis
The crude DCF-Gly was characterized by 1H- and 13C- nuclear
magnetic resonance (NMR) analysis. The 1H- and 13C- NMR spectra
were acquired at room temperature on an Inova 500 NMR spec-
trometer (Varian, Agilent technologies, Inc., Palo Alto, CA, USA),
equipped with a 5 mm triple resonance probe and z-axial gradients
operating at 500 MHz for 1H nuclei and 125 MHz for 13C nuclei.
Reference peaks for 1H and 13C spectra were respectively set to d
2.49 and d 39.5 for DMSO-d6. Two-dimensional double quantum
filtered spectroscopy (DQF-COSY) spectra were collected in the
phase-sensitive mode using the States method [22]. Typical data
were 2048 complex data points, 32 transients and 256 increments.
Shifted sine bell squared weighting and zero filling to 2 k  2 k
were applied before Fourier transform. The 2D 1H-13C gradient
heteronuclear single quantum correlation (adiabatic version)
(gHSQCAD) experiment was carried out using the pulse sequences
from the Varian user library [23]. The acquired spectra were pro-
cessed with ACD/NMR Processor Academic Edition (Advanced
Chemistry Development, Inc., Toronto, Canada) and are reported
in the supplementary materials (Suppl. Fig. 1A–D).2.3. Electrospun scaffolds production
All reagents and solvents were purchased from Sigma Aldrich.
The electrospun scaffolds were obtained from a 15% w/v PLA
(Poly(L-lactide), #93578, Mn 59.000, Sigma Aldrich) solutioncaffold for the controlled and targeted delivery of a synthetically obtained
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DCF-Gly ratio is 15:1) or none as control. 1,1,1,3,3,3-Hexafluoro-2
-propanol (HFIP, T63002, Sigma Aldrich) was used as solvent. Elec-
trospinning experiments were performed with a customized
device using 17 kV, a flow rate of 4 mL/h and an 18 G needle at
an electrode distance of 18 cm.
2.4. Scanning electron microscopy (SEM)
The morphology of the electrospun scaffolds was determined
using a scanning electron microscope (SEM, 1530 VP, Zeiss, Jena,
Germany). After platinum sputter coating, images were acquired
at a distance of 8 mm from the detector, a voltage of 15 kV and dif-
ferent magnifications. The ImageJ software supplied with the
DiameterJ plug-in was used for fiber diameter analysis.
2.5. Drug release experiments
For the drug release experiments, the scaffolds were incubated
at 37 C in a 1X Phosphate buffer saline (PBS, GibcoTM by Life Tech-
nologies GmbH, Darmstadt, Germany) solution. Nine mg of the
drug-loaded scaffolds were fully immerged in 3 mL of 1X PBS. At
different time points, 800 lL of the supernatant was taken to read
the absorbance (275 nm). After each measurement we returned
the supernatant to the scaffold containing solution. The amount
of the released drug was estimated according to a calculated cali-
bration curve. When using the Peppas equation [24], the release
is reported as percentage [25]. In this case, the absorbance of the
scaffold containing solution after 24 h was assumed as final value,
since no further release occurred after that time. Micro UV-
cuvettes (BrandTechTM 759210, BrandTM by Thermo Scientific, Darm-
stadt, Germany) and a TECAN Infinite 200 Reader were used for all
the UV measurements.
2.6. Contact angle measurements
Hydrophilicity of the electrospun substrates was analyzed using
contact angle measurements with an OCA 40 (DataPhysics Instru-
ments GmbH, Filderstadt, Germany). A water drop with the volume
of 2 lL was placed onto the sample and the contact angle was mea-
sured immediately after the water deposition using a video setup
and the SCA20 software (DataPhysics Instruments) as previously
described [26]. Final results were calculated from 16 measure-
ments obtained from 4 different scaffold pieces for each sample.
2.7. Uniaxial tensile testing
Electrospun scaffolds were cut into 10 mm  20 mm rectangu-
lar pieces and clamped into the uniaxial tensile testing device
(Electroforce 5500, ElectroForce Systems Group, Bose Corpora-
tion, Minnesota, USA). The exact sample dimensions were deter-
mined before each measurement and recorded with the software
for further calculations of the Young’s modulus (E) and the tensile
strength. The scaffolds were pulled to failure by applying a stretch
of 0.025 mm/s. The Young’s modulus was calculated from the ini-
tial linear slope of the stress versus strain curve for each measure-
ment. Measured values are presented as mean ± standard
deviation (each group n = 3).
2.8. Cell culture and seeding
All research was carried out in compliance with the rules for
investigation of human subjects, as defined in the Declaration of
Helsinki. This study was carried out in accordance with the institu-
tional guidelines and was approved by the local research Ethics
Committee (F-2012-078). After informed written consent wasPlease cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
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(HDFs) were isolated by enzymatic digestion as previously
described [27]. Cells were cultured in Dulbecco’s Modified Eagle
Medium (with L-Glutamine, DMEM11965092, GibcoTM, Life Tech-
nologies GmbH) supplemented with 10% fetal calf serum (FCS,
PAA Laboratories, Pasching, Austria) and 1% penicillin/strepto-
mycin (Life Technologies GmbH). Cells were cultured in an incuba-
tor at 37 C and in a 5% CO2 atmosphere. Cell culture medium was
changed every 3 days and cells were passaged or seeded using
trypsin-EDTA (15090046, PAA Laboratories) at approximately 70%
confluence.
2.9. Multiphoton microscopy (MPM)
A Titan:Sapphire femtosecond laser (MaiTai XF1 Spectra Phy-
sics, USA, Santa Clara) was used to generate 2-photon excitation.
An excitation wavelength of 710 nm and a laser power of
3.2 mW were employed. The spectral emission filter ranged from
425 to 509 nm. For the imaging of the drug encapsulation, punches
(Ø = 12 mm) of the scaffolds were put on Ibidi glass bottom dishes
(35 mm) and carefully pressed on the bottom with a cover glass
before analysis. HDFs morphology was assessed on glass bottom
dishes (Ibidi, 35 mm) with a density of 5 x 104 cells per dish. After
24 h, the medium was removed and 2 mL of fresh DMEM (+ 10%
FCS) was added. When the cells were incubated with the drug-
loaded scaffolds, punches (Ø = 28 mm) of previously sterilized
(254 nm, 2 h) scaffolds were given as well. In both cases the cells
were imaged after further 24 h. The laser power was in this case
adjusted to 18 mW. For the mean gray value intensity (GVI) anal-
ysis, ImageJ was used.
2.10. In vitro cytotoxicity assay
According to an ISO 10993 accredited protocol HDFs were
exposed to an extract of the samples. The test was carried out as
previously described [28]. In particular the electrospun scaffolds
were sterilized by UV irradiation (254 nm) for 2 h. 6cm2 of each
sample were then incubated in 1 mL FCS- and antibiotic-free
DMEM medium. After 24 h, seeded HDFs were exposed for further
24 h to the extracts supplied with 10% FCS. The extraction medium
was removed and a tetrazolium salt ([3-(4,5-dimethylthiazol-2-y
l)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo
lium], MTS; G3580, CellTiter 96Aqueous One Solution Cell Prolifer-
ation Assay, Promega, Mannheim, Germany) assay was performed
as per the manufacturer’s protocol. Briefly, 20 lL of MTS solution
were added to 100 lL of culture media. After incubation for
35 min at 37 C, the absorbance of each well was measured at
492 nm. The test was performed for a blind, a negative control
(NC; DMEM + 10% FCS) and a Sodium Dodecyl Sulfate (SDS, Life
Technologies GmbH, 1% in DMEM) treated positive control (PC).
For analysis, the NC was set to 100%.
2.11. Fluorescence lifetime imaging microscopy (FLIM)
FLIM was performed to assess reduced (phosphorylated) nicoti-
namide adenine dinucleotide (NAD(P)H) using time correlated sin-
gle photon counting (TCSPC) at an excitation wavelength of
710 nm and a laser power of 18 mW. FLIM data were recorded at
an acquisition time of 180 s for 512  512 pixels with 64 time
channels. The instrument response function was recorded using
urea crystals (Sigma Aldrich) at an excitation wavelength of
920 nm and a laser power of 4.5 mW for 120 s. The FLIM images
were calculated using the SPCImage software (Becker &Hickl
GmbH, Berlin, Germany). A two exponential decay fitting model
was employed at each pixel since NAD(P)H has two different life-
times [29]. Av2 < 1.1 was accepted for a good fitting. A binning fac-caffold for the controlled and targeted delivery of a synthetically obtained
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from 12 images obtained from 3 different dishes (4 images/dish)
for each sample.
2.12. Data analysis
All the reported graphs were plotted using MicrosoftTM Excel. All
data are presented as mean ± standard deviation (n = 4, unless sta-
ted otherwise in the materials and methods). Statistical signifi-
cance was determined by a Student’s two-tailed unpaired t-test;
p 6 0.01 was defined as statistically significant, unless stated
otherwise.
3. Results
3.1. Synthesis of a DCF prodrug via SPPS
The DCF-Gly derivative was chosen according to the predicted
values for its MW (=353.20 g/mol) and logP (=2.78), which were
estimated using Molinspiration, making it suitable for a transder-
mal delivery [14]. The synthetic scheme used for the DCF-Gly syn-
thesis is shown in Fig. 1. The desired product was obtained with a
high degree of purity (99%) according to NMR analysis (Suppl.
Fig. 1) and was recovered in a high yield (98%).
3.2. Production and characterization of the scaffolds
3.2.1. Electrospinning
PLA was dissolved in HFIP either alone or in presence of DCF-
Gly. Various electrospinning parameters were tested and those
leading to a stable Taylor cone and jet as well as to smooth and
uniform fibers were then used throughout the study. The condi-
tions were first defined for pure PLA and then adapted for the
drug-loaded scaffolds.
3.2.2. SEM und fiber diameter analysis
The morphology and fiber sizes of the PLA scaffold, the drug-
loaded scaffold and the scaffold after drug release (a.r.) was inves-
tigated using SEM (Fig. 2). It was possible to generate scaffolds
with a random fiber orientation. In all conditions, we obtained uni-
form fibers with no beads (Fig. 2A–F). After drug release, morpho-
logical changes were visible; however, the fibers were still uniform
and randomly oriented (Fig. 2G–I). Fiber sizes significantly
increased by the incorporation of the drug (PLA: 148 ± 9 nm versus
PLA + DCF-Gly: 180 ± 9 nm; p = 0.001). Despite the change in mor-
phology, there was no significant decrease in fiber size after drug
release (PLA + DCF-Gly: 180 ± 9 nm versus PLA + DCF-Gly a.r.:
170 ± 8 nm; p = 0.48).
3.2.3. Contact angle measurement
Wettability of the scaffolds was determined using contact angle
measurements (Fig. 3A–B). The analysis showed that the drug-
loaded scaffolds remained highly hydrophobic (PLA + DCF-Gly:
130.1 ± 8) and no significant changes were determined when
compared with the pure PLA scaffolds (PLA: 131 ± 7).Fig. 1. Reaction scheme for the synthesis of D
Please cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
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PLA is an elastic and electrospinnable polymer. No significant
differences were observed in regards to tensile strength (PLA:
1.84 ± 0.19 MPa versus PLA + DCF-Gly: 1.91 ± 0.18 MPa; p = 0.67)
and Young’s modulus (PLA: 27.4 ± 9.7 MPa versus PLA + DCF-Gly:
25.4 ± 1.2 MPa; p = 0.48) when comparing the pure electrospun
PLA with the drug-containing scaffold. Like the hydrophobicity,
the elastic modulus and tensile strength were not influenced by
the encapsulation of the DCF prodrug. The experimental curves
obtained for the PLA and the PLA + DCF-Gly scaffolds are shown
in Fig. 3C and D, respectively.
3.2.5. MPM analysis
MPM of the synthesized prodrug was employed for the visual-
ization of the drug encapsulation profiting from the presence of
an aromatic ring on the DCF molecule. Whereas there was no signal
detectable for pure PLA scaffolds (Suppl. Fig. 2), a strong signal was
obtained for the drug-loaded PLA + DCF-Gly scaffolds (Fig. 4A)
demonstrating that encapsulation with electrospinning was suc-
cessful. Furthermore, multiphoton laser-induced autofluorescence
signals were detected from the entire scaffold. Every fiber is clearly
visible, confirming that DCF-Gly is homogeneously distributed
throughout the scaffold and the single fibers. After drug release,
the signals significantly decreased or were absent (Fig. 4B). Only
a few fibers of the scaffold could be visualized suggesting that most
of the encapsulated drug had been successfully released from the
scaffold after the incubation in PBS. The obtained mean gray values
(Fig. 4C) were 82 ± 12 and 8.1 ± 1.1 before and after the drug
release, respectively. According to these values the percentage of
the not released drug was estimated to be approximately 10%.
3.2.6. Drug release experiments
After demonstrating that the drug was successfully encapsu-
lated within the PLA fibers, the ability of the scaffold to release
the drug was investigated. The absorbance at 275 nm of the PBS
solution, in which the scaffold was immerged, was constantly
monitored for the first 7 h (Fig. 5A). Thereafter, it was measured
again after 24, 48 and 72 h. The absorbance value was constant
after the first 24 h. This time was therefore set as the end point
measurement, considering that no more drug will be released after
that time until having a significant scaffold hydrolysis. According
to a calibration curve and assuming that no loss of the drug occurs
during the electrospinning process we could estimate that 89 ± 2%
of the encapsulated drug was released from the scaffold after 24 h.
The obtained data were also plotted in a logarithmic form (Fig. 5B)
using the equation developed by Peppas et al. [24]. Peppas equa-
tion offers a simple model to study the release mechanism of incor-
porated molecules from polymers. According to the value obtained
for the slope, which is lower than 0.45, the release undergoes a
Fickian diffusion [25].
3.2.7. In vitro cytotoxicity
The biocompatibility of the modified scaffold was assessed with
a MTS assay using a standardized protocol and HDFs (Fig. 6E). A
material is non-cytotoxic when the proliferation is higher thanCF-Gly via SPPS with H-Gly-2ClTrt Resin.
caffold for the controlled and targeted delivery of a synthetically obtained
oi.org/10.1016/j.actbio.2016.11.002
Fig. 2. Analysis of the morphology and fiber size of the electrospun scaffolds. A–F. SEM images of the electrospun scaffolds at different magnifications (a.r. = after release;
scale bars: A–C = 5 lm; D–F = 1 lm). G–I: Histograms of the fiber diameter distribution and the average fiber size.
Fig. 3. Wettability assessment and mechanical testing of the electrospun scaffolds. Drop shape analysis of the pure PLA (A) and the PLA-DCF-Gly containing (B) scaffold after
water deposition. Stress-Strain curves for pure PLA (C) and PLA + DCF-Gly (D).
G. Piccirillo et al. / Acta Biomaterialia xxx (2016) xxx–xxx 580% relative to the NC [30]. Accordingly, we determined that the
PLA scaffolds, either with or without the encapsulated DCF-Gly,
showed no cytotoxic effects (cell proliferation: PLA = 104 ± 6%;
PLA + DCF-Gly = 105 ± 7%). The assay was also performed with a
PLA scaffold containing the non-modified DCF (DCFONa) as a pos-
itive cytotoxic control [31]. In this case, a severe cytotoxicity (cell
proliferation = 16 ± 3%) was observed.
3.2.8. FLIM analysis
FLIM was performed to analyze endogenous NAD(P)H in HDFs
as a measure for metabolic changes in the target cells due to thePlease cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
Diclofenac prodrug to treat actinic keratosis, Acta Biomater. (2016), http://dx.dincubation together with the drug-loaded scaffolds. For FLIM anal-
yses, a two exponential decay was employed assuming to have two
different fluorescence lifetimes respectively for the free (s1) and
the protein-bound (s2)NAD(P)H [29]. The a1 represents the free
NAD(P)H contribution to the final lifetime values. Moreover, we
aimed to correlate the obtained data directly with the results that
arose from the MTS assay since the rate of tetrazolium reduction
reflects the general metabolic activity/rate of glycolytic NAD(P)H
[29]. No changes in the cell morphology could be observed for
the DCF-Gly-loaded and non-loaded scaffolds when compared to
the controls (Fig. 6A–C). The cells were elongated and showedcaffold for the controlled and targeted delivery of a synthetically obtained
oi.org/10.1016/j.actbio.2016.11.002
Fig. 4. MPM imaging of the DCF-Gly loaded scaffolds. MPM images (scale bar = 10 lm) of the DCF-Gly loaded scaffold before (A) and after (B) the drug release. Gray values
intensities obtained from the MPM images (C).
Fig. 5. Release profile of DCF-Gly from the PLA scaffold. Drug release analysis (A) and logarithmic fitting of the drug release data with Peppas equation (B). Data are presented
as mean ± standard deviation (n = 4).
Fig. 6. Cytotoxicity assessment using HDFs. MPM images of HDFs (A–D). HDFs treated with cell culture medium only as NC (A) or in presence of PLA (B), PLA + DCF-Gly (C)
and PLA + DCFONa (D) scaffolds. Scale bars equal 20 lm. Results of the accredited MTS-assay (E) and the FLIM analysis of alpha 1 using a biexponential decay (F).
6 G. Piccirillo et al. / Acta Biomaterialia xxx (2016) xxx–xxxthe typical shape of fibroblasts [32]. However, when exposed to
DCFONa, a significant morphological change was observed in the
MPM images (Fig. 6D) due to induced necrosis/apoptosis [32].
Here, the cytoplasm and the nucleus were clearly altered. This
morphological change correlated to a metabolic change accordingPlease cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
Diclofenac prodrug to treat actinic keratosis, Acta Biomater. (2016), http://dx.dto the a1 values of FLIM measurements. A significant decrease in
the free NAD(P)H level (a1; Fig. 6F) was observed for the PLA
+ DCFONa treated HDFs, but not for PLA or PLA + DCF-Gly exposed
cells (PLA + DCFONa: 63.9 ± 0.9% versus NC: 67.5 ± 0.8%; p = 0.001).
No significant changes in s1and s2 were detectable (Suppl. Fig. 3).caffold for the controlled and targeted delivery of a synthetically obtained
oi.org/10.1016/j.actbio.2016.11.002
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Three-dimensional scaffolds are of growing interest among sci-
entists for applications in the field of tissue engineering or as drug
delivery systems [33,34]. Among the currently employed polymers,
PLA may be the most suitable material for the production of slowly
biodegradable scaffolds for biomedical applications [35]. Thus, PLA
is also a suitable material to produce systems for a controlled drug
delivery [36]. DCF is one of the most potent NSAIDs [37,38]. It has
been used for the treatment of many different diseases such as
osteoarthritis [39] and AKs [40]. Since its approval, a number of dif-
ferent DCF-containing products have been developed with the goal
of improving efficacy, tolerability, and patient convenience [41–
45]. However, no new formulations of DCF for the treatment of
AKs have been proposed since its FDA approval in 2002 [9]. The
DCF formulation proposed in this work should offer a new option
for the local treatment of AKs. DCF has unique chemical features.
For example, the amine function is a very weak base when com-
pared to other secondary amines [46]. This feature was utilized
in this study to handle DCF as an amino acid analogue in SPPS. In
particular, DCF was linked to a glycine residue by forming an ami-
dic bond to obtain a derivative (DCF-Gly) with a lower logP when
compared to DCF (estimated logP: DCF-Gly = 2.78 versus
DCF = 4.96). This is necessary in order to be suitable for a transder-
mal delivery [14]. The formation of an amidic bond is a well-used
strategy for the synthesis of prodrugs since it may be easily cleaved
by enzymatic hydrolysis [47,48]. Solid phase synthesis represents a
clean, versatile and efficient way to avoid the use of large amounts
of solvents and reagents [48]. Amide prodrugs of DCF have already
been synthesized by Kumar et al. [49]. However, the synthetic
scheme that was proposed in this study allowed them to reach
only yields about 60% [49]. Here, we obtained a quantitative yield
of 98%. Moreover, we obtained the free amino acid derivative
instead of the protected ester [49], which is crucial when aiming
for obtaining a proper hydrophobicity for the synthesized prodrug.
For the synthesis of the DCF-Gly prodrug, a 2-Chloro Trityl Chloride
(CTRL-Cl) resin was employed. The CTRL-Cl resin allows the syn-
thesis of peptides with a carboxylic group at the C-terminus [50]
and is compatible with the Fluorenyl-9-methoxycarbonyl protect-
ing group chemistry [51,52]. Compared to the other resins, the
CTRL-Cl one has not only the advantage to produce peptides free
from diastereomeric side-products [50–52], but offers the possibil-
ity to operate the cleavage under mild acidic conditions (either 1%
trifluoroacetic acid/DCM [51] or AcOH/TFE/DCM [52]), which is
required when handling protected or modified peptides. The
opportunity of binding DCF to different amino acid residues and
even to longer peptide chains without the need of further purifica-
tion could be employed to obtain many different DCF derivatives.
This is potentially very useful considering the variety of medical
applications of DCF [37–40]. The results obtained in this study by
binding DCF to a glycine residue are promising since we achieved
a high yield and a great degree of purity. However, the versatility
of this synthesis has to be further investigated. The synthesized
DCF-Gly prodrug was successfully incorporated in a PLA scaffold
using electrospinning. The obtained electrospun scaffolds were
then characterized in order to demonstrate that it is a suitable sys-
tem for the topical treatment of AKs. In particular, the morphology
of the scaffold was investigated with SEM. This technique is the
often used for the investigation of nanostructures. It is reliable
and allows high magnifications with a good resolution [53]. Thus
this analysis was necessary to investigate the scaffold morphology,
analyze the diameter distributions and compare them. The SEM
investigation showed a homogeneous fibrous structure of the gen-
erated electrospun scaffolds. For the drug-loaded scaffolds, a sig-
nificant increase in the fiber diameters could be observed. ThisPlease cite this article in press as: G. Piccirillo et al., Electrospun poly-L-lactide s
Diclofenac prodrug to treat actinic keratosis, Acta Biomater. (2016), http://dx.dmay be due to the increase in viscosity of the electrospun solution
and also the presence of the drug molecules within the polymeric
fibers [54]. The mean values of the fiber diameter remained still
lower than 200 nm, and a regular fibrous structure with no beads
was maintained. The increased fiber diameters after drug encapsu-
lation did not affect the mechanical properties such as the Young’s
modulus or the tensile strength of the electrospun scaffold. Soli-
man et al. [55] and Milleret et al. [56] showed in previous studies
that fiber diameter and orientation, as well as scaffold porosity can
impact the mechanical properties of the scaffolds. In particular,
they both proved that an increase in the fiber diameter leads to a
significant increase in the Young’s modulus [55,56]. However, they
analyzed differences in the diameter values that were in the lm
range [55,56]. In our work, the variation in the fiber diameters is
probably too low to significantly impact the investigated mechan-
ical properties. By adding DCF-Gly, the wettability of the scaffolds
was also not affected. The scaffolds remained highly hydrophobic
as it is described for pure PLA [26]. We have chosen PLA as the drug
carrier, since hydrophobicity is important to ensure the drug diffu-
sion from the scaffold into the lesion [57,58].
DCF-Gly encapsulation could be easily visualized using MPM
due to the ability to selectively induce DCF autofluorescence [59].
One of the advantages of the MPM technique is the ability to image
non-invasively and thus without destroying or modifying the sam-
ples [60,61]. This enables a simple, in situ quality control. MPM has
already been used to image scaffolds with and without a fibrous
structure [62,63]; however, a good contrast or resolution could
not be achieved so far. Interestingly, we obtained a good contrast
using a very low laser power (3.2 mW). This approach is promising
and could be potentially extended to different substrates since a
great number of drugs and endogenous molecules are autofluores-
cent when excited at defined wavelengths. Here, we used MPM to
show successful encapsulation and release of the prodrug. By cal-
culating the GVI, it was possible to estimate the amount of non-
released DCF-Gly. After 24 h, 10% of DCF-Gly remained in the scaf-
fold, which is comparable to values from literature described by
Sidney et al. for previously developed DCF eluting systems [43].
However, the initial burst release was 60% [43], and in our study
only 20%. Initial burst of drug release is related to drug type, drug
concentration, polymer hydrophobicity and to the scaffold nanos-
tructure [64–66]. In contrast to the previously described eluting
system, the one described in this study utilized a fibrous structure
since it was obtained via electrospinning. Moreover, hydrophobic
PLA was used as the only polymer while Sidney et al. used a mix-
ture of the hydrophobic polyesther PLGA (poly-D,L-lactic acid-co-
glycolic acid)with the more hydrophilic PEG (poly-ethylene glycol)
[43]. In addition, the synthesized DCF-Gly prodrug was used as free
acid instead of the Diclofenac sodium salt DCFONa. Carboxylic
acids have a lower water solubility than the correspondent sodium
salts thus showing a slower and more controlled diffusion over the
time [67]. Due to these features, the formulation that is proposed
here helps to reduce the initial burst release and to have a sus-
tained drug release from the scaffold over the first 24 h. Further-
more, we investigated the amount of the released drug in the
supernatant. It has been shown before, that drug release can be
controlled and influenced by changing various parameters such
as hydrophobicity, fiber size or drug concentration [68]. In our sys-
tem, the encapsulated DCF-Gly was effectively released from the
scaffold following a controlled Fickian diffusion according to the
spectrophotometric measurements and the Peppas equation. This
equation has already been employed as a simple model to investi-
gate the drug release from electrospun scaffolds [69,70]. For the
here characterized scaffold, the release mechanism undergoes a
Fickian diffusion due to a very low diffusion coefficient of 0.29.
The encapsulated drug is mostly (90%) released within the firstcaffold for the controlled and targeted delivery of a synthetically obtained
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ing that DCF is used as a daily treatment to cure AKs [10]. Further-
more, the in vitro biocompatibility of the drug-containing scaffold
was tested by performing a MTS cell proliferation assay. This test
allows for a quantitative evaluation of cytotoxicity [71] and satis-
fies the international standard (ISO 10993-5). In contrast to
DCFONa, DCF-Gly is non-cytotoxic. It is well known that DCF
induces cell death [31,72], suggesting that the newly synthesized
molecule is a promising non-cytotoxic prodrug for treating AK. In
addition, we investigated the effect of DCF on HDFs after its release
from the PLA scaffold employing MPM coupled with FLIM. For the
analysis NAD(P)H was chosen as a target [29]. This approach allows
the monitoring of changes in cell morphology and metabolism
without the need of staining or the interruption of cell culture.
The MPM analysis allowed us to image morphological changes in
HDFs after the DCF treatment. It is known that DCF induces cell
death due to a mitochondrial injury [72]. Specifically, either apop-
tosis or necrosis is induced depending on how many mitochondria
are affected [31]. In this work we aimed to correlate the observed
morphological changes to the induced cell death as previously
described by Seidenari et al. [32]. In particular, cells that showed
a nuclear and cytoplasmic condensation were assessed as apop-
totic while cells showing both swelling and vacuolation of the
cytoplasm were considered to undergo necrosis [32]. According
to the morphological observations obtained with MPM, we suggest
that both apoptotic and necrotic events occur after the DCF treat-
ment. FLIM allowed the marker-free detection of the metabolic
changes after the DCF treatment. In particular, a significant
decrease in the rate of glycolytic NAD(P)H [29] could be detected.
Our FLIM data supported the results obtained from the MTS assays.
Our data show that employing a drug-loaded PLA scaffold as a
drug-releasing wound dressing to treat AKs could be a very useful
and promising alternative to current treatment strategies. It would
help to control the daily dosage, thus significantly reducing side-
effects, and be applicable as targeted therapy. In addition, the here
proposed formulation could be very useful after surgical proce-
dures, photodynamic- and cryotherapy because it would ensure a
protection of the treated area and favor the wound healing
[73–75]. It has been reported that the application of drug-free elec-
trospun PLA nanofibrous scaffolds as wound dressing materials
already enhance the recovery process [76–78], indicating that the
here presented combination of PLA and DCF-Gly is a highly inter-
esting candidate for AK treatment. To further improve the func-
tional performance of DCF-Gly, the usage of coaxial and tri-axial
electrospinning might be favorable [79,80]. Although this study
introduces a potential beneficial system, the effectiveness to treat
AK needs to be further investigated in adequate in vivo models.
In order to confirm an enhanced transdermal delivery of the syn-
thesized DCF-Gly prodrug compared to DCF [81], further experi-
ments are necessary.5. Conclusions
In this study, an electrospun PLA scaffold loaded with a synthet-
ically obtained DCF prodrug was generated and characterized. The
proposed DCF-Gly synthesis based on the use of SPPS is novel and
promising. Compared to non-modified DCF, DCF-Gly is non-
cytotoxic and therefore potentially a more suitable drug to treat
AK. The electrospun PLA + DCF-Gly scaffold represents an interest-
ing drug releasing system that enables a controlled and targeted
delivery of DCF-Gly for the topical treatment of AKs.Disclosure
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